BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 12, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Azilsartan medoxomil regulatory update

The European Commission approved Edarbi azilsartan medoxomil from Takeda to treat hypertension. Takeda plans to launch...

Read the full 59 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >